SURUSS in perspective

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 6, 2004, Pages 521-531

  Wald, N J ^a   Rodeck, C ^b   Hackshaw, A K ^a   Rudnicka, A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

AMNIOCENTESIS; CHORION VILLUS; COST EFFECTIVENESS ANALYSIS; DELIVERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DOWN SYNDROME; FETUS ECHOGRAPHY; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCREENING TEST; ULTRASOUND; URINALYSIS; URINE;

ANTIGENS; BIOLOGICAL MARKERS; COSTS AND COST ANALYSIS; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; MATERNAL AGE; NECK; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TROPHOBLASTS; ULTRASONOGRAPHY, PRENATAL;

EID: 2942601027     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00193.x     Document Type: Review

References (27)

1. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104. Available: http:// www.ingentaselect.com/rsm/09691413/v10n2/ contp1-1.htm.
2. Wald N, Rodeck C, Rudnicka A, Hackshaw A. Nuchal translucency and gestational age. Prenat Diagn 2004;24:150-153.
3. Wald N, Hackshaw A. Tests using multiple markers. In: Wald NJ, Leck I, editors. Antenatal and Neonatal Screening, 2nd edition. Oxford: Oxford University Press, 2000:23-57.
4. Morris JK, Mutton DE, Alberman E. Revised estimates of maternal age specific live birth prevalence of Down's syndrome in the absence of antenatal screening and selective termination. J Med Screen 2002;9:2-6.
5. Office for National Statistics. Birth Statistics, Series FM1, Numbers 25-27. London: HMSO, 1996, 1997, 1998.
6. Gilbert RE, Augood C, Gupta R, et al. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423-425.
7. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-247.
8. Gosden C, Tabor A, Leck IL et al. Amniocentesis and chorionic villus sampling. In: Wald N, Leck I, editors. Antenatal and Neonatal Screening, 2nd edition. Oxford: Oxford University Press, 2000:470-516.
9. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynaecol 2003;22:142-148.
10. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-145.
11. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-887.
12. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-268.
13. Wald NJ, Huttly WJ. Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome. Prenat Diagn 1999; 19:1083.
14. Wald NJ, Hackshaw AK, Huttly W, Kennard A. Empirical validation of risk screening for Down's syndrome. J Med Screen 3:185-187.
15. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219-225.
16. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening programme for trisomy 21 at 10-14 weeks using fetal NT, maternal serum free β-hCG and PAPP-A. Ultrasound Obstet Gynecol 1999;13: 231-237.
17. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemical in a one-step clinic: a review of three years prospective experience. Br J Obstet Gynaecol 2003;110:281-286.
18. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143-153.
19. Wald NJ, Densem JW, George L, et al. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997;17:285-290.
20. Nicolaides KH, Snijders RJM, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998;18:519-521.
21. de Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, van Lith JMM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999;19:458-462.
22. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003;22:144-148.
23. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-467.
24. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-836.
25. Chen J, Heffley D, Beazoglu T, Benn PA. Utilization of amniocentesis by women screening positive for Down syndrome on the second-trimester Triple test. Community Genet 2000;3:24-30.
26. Whittle M. Down's syndrome screening: where to now? Br J Obstet Gynaecol 2001;108:559-561.
27. Cooper Y. In favour of motherhood. Guardian 2001 (April 30).